CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 31 enrolled
Drug / intervention
TAK-816biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02074345
NCT02074345Phase 3Completed
CompareCT.gov

A Phase III, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of Intramuscular TAK-816 in Healthy Infants

Takeda·interventional·Posted Feb 28, 2014·Updated Apr 26, 2016

In Brief

A Phase 3 clinical trial evaluating TAK-816 for Healthy Volunteers and Haemophilus Influenzae Type b, Prevention. Completed, enrolled 31 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and immunogenicity of intramuscular TAK-816 in healthy Japanese infants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Haemophilus Influenzae Type b, Prevention
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 28, 2014
Enrollment StartMar 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.3 years ago

Interventions

TAK-816biological

TAK-816 intramuscular injection